Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer

Abstract

We identified molecular features associated with the response to the REGONIVO and TASNIVO, particularly those related to tumor microenvironmental factors. These findings are likely to contribute to the development of biomarkers to predict treatment efficacy for MSS/pMMR CRC and future immunotherapy combinations for treatment.